EyeTechCare has raised US$9 million
EyeTechCare has raised US$9 million, with funds provided by Lyon-based insurance company SHAM, a first time investor, and Crédit Agricole Private Equity (CAPE), one of EyeTechCare’s existing shareholders.
Founded in 2008 and based in Rillieux-la-Pape, near Lyon, France, EyeTechCare provides innovative medical non-invasive devices to permanently cure glaucoma, the first cause of blindness in developed countries.
The funds raised in this second financing will be used to complete the first clinical trial on humans, as well as establish the manufacturing facilities and the sales and marketing force required for this first product. The market launch is scheduled for early 2011.
Oaklins’ team in France reviewed the strategy with the board and organized a fundraising with specialized venture funds.
Talk to the deal team
Thibaut de Monclin
Alcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.Learn more
A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.Learn more
Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.Learn more